The University of Southampton
University of Southampton Institutional Repository

Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study

Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study
Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study
BACKGROUND:
Fentanyl citrate buccal tablets are indicated for the treatment of breakthrough pain (BTP) in cancer, in adults who are receiving maintenance opioid therapy for chronic cancer pain.
OBJECTIVE:
One of the objectives of this study was to describe the utilization characteristics of patients prescribed fentanyl buccal and to assess how the product is being used in relation to the terms of license of marketing approval.
METHODS:
An observational post-marketing cohort study was conducted. For the analysis of this study, exposure data were collected from dispensed prescriptions issued by general practitioners (GPs) between March 2009 and June 2011. Outcome data (indication, event, patient demographic and selected clinical characteristics) were collected by sending questionnaires to GPs at least 6 months after the drug was first prescribed. Summary descriptive statistics were calculated.
RESULTS:
The cohort consisted of 551 patients, of which 54.8% (n = 302 patients) were female. The median age for the cohort was 62 years (interquartile range: 50-72 years), with one patient (0.2%) aged less than 18 years. A primary indication of BTP in cancer was reported for 61.9% (n = 341) patients. Regular opioid therapy was reported upon starting the treatment for 383 patients (69.5% of cohort). In total, 69 patients (12.5%) had one or more contraindications for use. The most frequent initial titration dose was 100 μg/day (n = 247).
CONCLUSIONS:
The final study results show that fentanyl buccal is largely being prescribed according to the terms of the license in general practice in England, but off-licence use and use in the presence of contraindications and warnings have been reported.
1090-3801
506-512
Osborne, V.
e04aa392-1cd9-44a2-8b06-ac5306524213
Layton, D.
ffe4fa31-837c-46bf-aa15-fe28cbf0ca7f
Fogg, Carole
42057537-d443-462a-8944-c804252c973b
Al-Shukri, M.
7491db8c-8c08-400d-87c6-23462602fe38
Shakir, S. A. W.
aeb2fdf3-8ade-4c67-9a0f-de3f1139b2c7
Osborne, V.
e04aa392-1cd9-44a2-8b06-ac5306524213
Layton, D.
ffe4fa31-837c-46bf-aa15-fe28cbf0ca7f
Fogg, Carole
42057537-d443-462a-8944-c804252c973b
Al-Shukri, M.
7491db8c-8c08-400d-87c6-23462602fe38
Shakir, S. A. W.
aeb2fdf3-8ade-4c67-9a0f-de3f1139b2c7

Osborne, V., Layton, D., Fogg, Carole, Al-Shukri, M. and Shakir, S. A. W. (2014) Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study. European Journal of Pain, 18 (4), 506-512. (doi:10.1002/j.1532-2149.2013.00389.x).

Record type: Article

Abstract

BACKGROUND:
Fentanyl citrate buccal tablets are indicated for the treatment of breakthrough pain (BTP) in cancer, in adults who are receiving maintenance opioid therapy for chronic cancer pain.
OBJECTIVE:
One of the objectives of this study was to describe the utilization characteristics of patients prescribed fentanyl buccal and to assess how the product is being used in relation to the terms of license of marketing approval.
METHODS:
An observational post-marketing cohort study was conducted. For the analysis of this study, exposure data were collected from dispensed prescriptions issued by general practitioners (GPs) between March 2009 and June 2011. Outcome data (indication, event, patient demographic and selected clinical characteristics) were collected by sending questionnaires to GPs at least 6 months after the drug was first prescribed. Summary descriptive statistics were calculated.
RESULTS:
The cohort consisted of 551 patients, of which 54.8% (n = 302 patients) were female. The median age for the cohort was 62 years (interquartile range: 50-72 years), with one patient (0.2%) aged less than 18 years. A primary indication of BTP in cancer was reported for 61.9% (n = 341) patients. Regular opioid therapy was reported upon starting the treatment for 383 patients (69.5% of cohort). In total, 69 patients (12.5%) had one or more contraindications for use. The most frequent initial titration dose was 100 μg/day (n = 247).
CONCLUSIONS:
The final study results show that fentanyl buccal is largely being prescribed according to the terms of the license in general practice in England, but off-licence use and use in the presence of contraindications and warnings have been reported.

This record has no associated files available for download.

More information

Accepted/In Press date: 22 July 2013
Published date: 5 March 2014

Identifiers

Local EPrints ID: 437026
URI: http://eprints.soton.ac.uk/id/eprint/437026
ISSN: 1090-3801
PURE UUID: fd30cb3f-2e52-406b-b477-5a216ba7eb70
ORCID for Carole Fogg: ORCID iD orcid.org/0000-0002-3000-6185

Catalogue record

Date deposited: 15 Jan 2020 17:32
Last modified: 17 Mar 2024 03:56

Export record

Altmetrics

Contributors

Author: V. Osborne
Author: D. Layton
Author: Carole Fogg ORCID iD
Author: M. Al-Shukri
Author: S. A. W. Shakir

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×